Dr. Ewan Gibb Develops Molecular Classifier to Improve Risk Stratification in Early Low-Grade Bladder Cancer

Early-stage, low-grade bladder cancer is often described as “low risk,” yet a substantial proportion of patients experience recurrences that remain difficult to predict using conventional clinical criteria. Traditional risk assessment, such as the International Bladder Cancer Group (IBCG) guidelines, relies primarily on pathological features like tumor grade, stage, and size. While these remain essential, they do not fully capture the underlying molecular heterogeneity of bladder tumors.

In a new study published in European Urology Oncology, Dr. Ewan Gibb from the Vancouver Prostate Centre, and colleagues introduce a molecular classifier that leverages long non-coding RNA (lncRNA) signatures to identify hidden biological risk within tumors that are clinically classified as low-grade. As Dr. Gibb explains, “This classifier helps uncover the tumors that look low-risk but carry hidden recurrence potential, potentially giving clinicians a molecular roadmap to guide patient care.”

Long non-coding RNAs are transcripts that do not encode proteins but serve as sensitive indicators of cellular state and tumor biology. By analyzing these patterns, the classifier distinguishes tumors with a higher likelihood of recurrence from those genuinely at low risk. Importantly, the classifier is designed to complement established clinical risk models, providing additional prognostic information without disrupting standard workflows.

The study demonstrates that this classifier is particularly informative for patients classified as intermediate-risk under existing clinical guidelines. In these cases, therapeutic decisions, such as the intensity of surveillance or the consideration of adjuvant therapy, are often uncertain. The classifier provides a biologically grounded readout that could inform personalized follow-up strategies, improve risk communication, and may ultimately support better patient outcomes.

This work exemplifies the Vancouver Prostate Centre’s commitment to translational research, bridging molecular discovery with clinical practice. The classifier represents a step toward precision urologic oncology, where molecular profiling can complement existing clinical risk models to better refine patient management.

🌐Click here to read the full publication:
https://euoncology.europeanurology.com/article/S2588-9311(26)00057-X/fulltext